Literature DB >> 33786285

Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor.

Shigeru Tanaka1,2, Shuhei Hayashi3,4, Yoshitaka Isobe3, Eiichi Maruyama3, Hiroaki Ozawa5, Motoyasu Okuno3, Masaru Kondo1.   

Abstract

SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Aggressive thoracic tumor; Immune checkpoint inhibitor; SMARCA4

Year:  2021        PMID： 33786285      PMCID： PMC7947161          DOI： 10.1007/s13691-021-00472-4

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN： 2192-3183


  10 in total

1.  Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.

Authors:  Leora Witkowski; Jian Carrot-Zhang; Steffen Albrecht; Somayyeh Fahiminiya; Nancy Hamel; Eva Tomiak; David Grynspan; Emmanouil Saloustros; Javad Nadaf; Barbara Rivera; Catherine Gilpin; Ester Castellsagué; Rachel Silva-Smith; François Plourde; Mona Wu; Avi Saskin; Madeleine Arseneault; Rouzan G Karabakhtsian; Elizabeth A Reilly; Frederick R Ueland; Anna Margiolaki; Kitty Pavlakis; Sharon M Castellino; Janez Lamovec; Helen J Mackay; Lawrence M Roth; Thomas M Ulbright; Tracey A Bender; Vassilis Georgoulias; Michel Longy; Andrew Berchuck; Marc Tischkowitz; Inga Nagel; Reiner Siebert; Colin J R Stewart; Jocelyne Arseneau; W Glenn McCluggage; Blaise A Clarke; Yasser Riazalhosseini; Martin Hasselblatt; Jacek Majewski; William D Foulkes
Journal:  Nat Genet       Date:  2014-03-23       Impact factor: 38.330

2.  Clinicopathologic Characteristics of BRG1-Deficient NSCLC.

Authors:  Ibiayi Dagogo-Jack; Alexa B Schrock; Marina Kem; Nicholas Jessop; Jessica Lee; Siraj M Ali; Jeffrey S Ross; Jochen K Lennerz; Alice T Shaw; Mari Mino-Kenudson
Journal:  J Thorac Oncol       Date:  2020-01-24       Impact factor: 15.609

3.  Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.

Authors:  C Henon; J-Y Blay; C Massard; O Mir; R Bahleda; S Dumont; S Postel-Vinay; J Adam; J-C Soria; A Le Cesne
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

4.  Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC.

Authors:  Huaqiang Zhou; Jiayi Shen; Jiaqing Liu; Wenfeng Fang; Li Zhang
Journal:  J Thorac Oncol       Date:  2020-08       Impact factor: 15.609

5.  Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report.

Authors:  Yuki Iijima; Rie Sakakibara; Masahiro Ishizuka; Takayuki Honda; Tsuyoshi Shirai; Tsukasa Okamoto; Tomoya Tateishi; Hiroyuki Sakashita; Meiyo Tamaoka; Akira Takemoto; Yuichi Kumaki; Sadakatsu Ikeda; Yasunari Miyazaki
Journal:  Immunotherapy       Date:  2020-05-03       Impact factor: 4.196

Review 6.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

7.  Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.

Authors:  Reinhard Schneppenheim; Michael C Frühwald; Stefan Gesk; Martin Hasselblatt; Astrid Jeibmann; Uwe Kordes; Markus Kreuz; Ivo Leuschner; Jose Ignacio Martin Subero; Tobias Obser; Florian Oyen; Inga Vater; Reiner Siebert
Journal:  Am J Hum Genet       Date:  2010-02-04       Impact factor: 11.025

8.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

9.  SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.

Authors:  Francois Le Loarer; Sarah Watson; Gaelle Pierron; Vincent Thomas de Montpreville; Stelly Ballet; Nelly Firmin; Aurelie Auguste; Daniel Pissaloux; Sandrine Boyault; Sandrine Paindavoine; Pierre Joseph Dechelotte; Benjamin Besse; Jean Michel Vignaud; Marie Brevet; Elie Fadel; Wilfrid Richer; Isabelle Treilleux; Julien Masliah-Planchon; Mojgan Devouassoux-Shisheboran; Gerard Zalcman; Yves Allory; Franck Bourdeaut; Francoise Thivolet-Bejui; Dominique Ranchere-Vince; Nicolas Girard; Sylvie Lantuejoul; Francoise Galateau-Sallé; Jean Michel Coindre; Alexandra Leary; Olivier Delattre; Jean Yves Blay; Franck Tirode
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

10.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.

Authors:  Natasha Rekhtman; Joseph Montecalvo; Jason C Chang; Deepu Alex; Ryan N Ptashkin; Ni Ai; Jennifer L Sauter; Brie Kezlarian; Achim Jungbluth; Patrice Desmeules; Amanda Beras; Justin A Bishop; Andrew J Plodkowski; Mrinal M Gounder; Adam J Schoenfeld; Azadeh Namakydoust; Bob T Li; Charles M Rudin; Gregory J Riely; David R Jones; Marc Ladanyi; William D Travis
Journal:  J Thorac Oncol       Date:  2019-11-18       Impact factor: 15.609
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.